NEWS : CIMS Healthcare Excellence Awards 2017- Best Hospital Unit in Oncology & Individual Excellence in the field of Operations * Padmashree Dr. Ramakant Deshpande, Executive Chairman and Director of ACI, receiving an award for the Best Healthcare Entrepreneur at Global Awards for Excellence in Quality Management & Leadership * ACI DAYCARE-BORIVALI 4 Feb launching of centre by the hands of cabinet Minister Shree Vinod Tawde & sitting MP Shree Gopal Shetty * Click Here To Take Appointment!!! * We have Sucessfully performed 250 Robotic Surgery till date *
BLOG : Afatinib Superior to Erlotinin Liquid Biopsy gives 100% accuracy Head and Neck New Urinary Molecular Test

Recently details of the LUXLung 8 phase 3 trial became available. This study compared afatinib with erlotinib as second-line treatment for squamous cell carcinoma of the lung. Afatinib was better with respect to all parameters – median progression-free survival, overall survival and patient-reported quality of life outcome (using the European Organization for Research and Treatment…

In a recent study published in the famous journal JAMA Oncology?, Sacher and colleagues have shown the true value of liquid biopsy. Blood of the patients with advanced lung cancer was used to do droplet digital polymerase chain reaction (ddPCR) assay for detecting common EGFR and KRAS mutations.? Over one year, the study involved 180…

head and neck cancers form almost a quarter of the cancer burden in India. Several of such patients are dependent on their voice for livelihood (eg lawyers). Is it possible to offer them good chance of cure from cancer while still preserving their voice? The answer is yes, in specific instances. Recently neoadjuvant chemotherapy for…

A non invasive urine exosome gene expression assay is good news for Prostate screening. A urinary 3-gene expression assay discriminates high-grade (??GS7) versus low-grade (GS6) prostate cancer and benign disease. ?This will prevent overdiagnosis and help better management of individual patients.

Patients with Chronic Myeloid Leukemia (CML) typically a translocation between chromosome 9 and 22 – resulting in what is called the philadelphia chromosome. At Asian Cancer Institute, we know that this is not enough information to treat patients correctly. As the time passes, addtional chromosomal abnormalities (ACA) can emergence and need to be monitored. Based…

Gastrointestinal stromal tumors (GISTs), which lack KIT and PDGFRA gene mutations (wild type), are seen mainly in children and respond poorly to standard targeted therapy. At Asian Cancer Institute, we know how to focus on a personalized approach for such patients to improve outcome. ?How do we do this? We are up to date and…

This month Xalkori (crizotinib) was approved by the U.S. Food and Drug Administration to treat advanced non-small-cell lung cancer (NSCLC) with tumors that have a rareROS1 gene mutation. This is in addition to the drug’s approval (in 2011) for ALK positive advanced NSCLC. At Asian Cancer Institute, we have ?renown international experts who have contributed…

Patients with chronic myeloid leukemia (CML) are always worried when their WBC Count increases. At Asian Cancer Institute our expert Medical Oncologists and Hematologist understand very well which of such patients have a problem and which don’t. We know that significant number of patients treated with the tyrosine kinase inhibitor (TKI) dasatinib experience increase in…

?Recently the Journal of Clinical Oncology, published finding that persons heterozygous for the CHEK2*1100delC germline mutation not only have a higher risk of breast cancer, but also a much higher risk for other cancers as well. CHEK2 is a cell-cycle checkpoint regulator. The study involved data from 86,975 individuals between 2003 and 2010. Among these,…

Meta-analysis of 15 studies showed that Prophylactic bilateral salpingo-oophorectomy (PBSO) and bilateral prophylactic mastectomy (BPM) were both associated with a decreased Breast Cancer risk in BRCA1/2 mutation carriers. Similar findings were observed in BRCA1 and BRCA2 mutation carriers separately. Moreover, contralateral prophylactic mastectomy (CPM) significantly decreased contralateral BC incidence in BRCA1/2 mutation carriers. In addition,…

Left Menu Icon